New p53-based anti-cancer therapeutic strategies
- 1 December 1998
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 15 (4) , 222-228
- https://doi.org/10.1007/bf02787204
Abstract
Thep53 gene is frequently mutated in human tumours and therefore an important target for therapeutic intervention. Several p53-based strategies for treatment of cancer are currently under development.p53 gene therapy has resulted in tumour regression in patients with lung cancer. A mutant adenovirus can obliterate tumour cells carrying mutant p53 or lacking p53, but is unable to replicate in normal cells. Furthermore, current studies suggest that reactivation of mutant p53 proteins in tumours using small p53-activating molecules may initiate p53-dependent apoptosis and thus eliminate the tumour.Keywords
This publication has 56 references indexed in Scilit:
- From Bench Top to BedsideScience, 1997
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Bax suppresses tumorigenesis and stimulates apoptosis in vivoNature, 1997
- Cancer Cell CyclesScience, 1996
- Induction of the growth inhibitor IGF-binding protein 3 by p53Nature, 1995
- Allosteric activation of latent p53 tetramersCurrent Biology, 1994
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Regulation of the specific DNA binding function of p53Cell, 1992